HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Acetaminophen warnings

This article was originally published in The Tan Sheet

Executive Summary

Current labeling of OTC acetaminophen products is adequate and an additional general allergy warning or one concerning cross-reactivity for aspirin-sensitive patients is not warranted, McNeil Consumer Healthcare states in comments to FDA. The comments are in response to a June 9 submission filed by Whitehall-Robins (marketer of the ibuprofen analgesic Advil) arguing acetaminophen has allergenic potential and should be required to carry warnings (1"The Tan Sheet" July 5, In Brief). In its response, McNeil cites four new studies and a chart showing a lower incidence of allergic adverse events related to acetaminophen use than with ibuprofen, naproxen sodium and other ingredients

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS140221

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel